Literature DB >> 17035510

Biocompatibility of septal defect closure devices.

Matthias Sigler1, Christian Jux.   

Abstract

OBJECTIVE: Despite their clinical introduction 10 years ago, no human series on the healing response to Amplatzer and Starflex devices in humans have been reported yet. We sought to investigate the biocompatibility of Amplatzer and Cardioseal/Starflex septal occluder devices in humans and compare the findings to results in experimental animals.
METHODS: The healing response of Amplatzer and Cardioseal/Starflex septal occluder devices in humans (n = 12, follow-up periods from 5 days to 4 years) and in experimental animals (n = 32, follow-up periods from 4 days to 1 year) was studied using a uniform work up protocol. Histological sections of paraffin-wax-embedded or methacrylate-embedded specimen and scanning electron microscopy were used for biocompatibility screening.
RESULTS: Neoendothelialisation of all examined devices was complete after 3 months in vivo. Protruding metal frame parts, like screw threads and spring arms, were covered last. The initial deposition of fibrin and blood cells on the polyester fabric was subsequently organised by ingrown fibroblastic cells. Loosely arranged and poorly vascularised young granulation tissue was transformed time-dependently into quiescent fibre-rich connective repair tissue poor of cellular and capillary vessel components. Consistently, a mild chronic inflammatory response directed against textile fibres of both types of implants characterised by lymphocytic infiltration and multinucleated foreign body giant cells was observed equally in human and animal explants.
CONCLUSIONS: Systematic biocompatibility screening in a series of explanted human septal occluder devices showed results corresponding to findings in animal studies with regard to neoendothelialisation, cellular organisation of initial thrombus and persisting immune response.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17035510      PMCID: PMC1861502          DOI: 10.1136/hrt.2006.098103

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  26 in total

1.  Transcatheter Closure of Secundum Atrial Septal Defects Using the Amplatzer Septal Occluder: Clinical Experience and Technical Considerations.

Authors: 
Journal:  Curr Interv Cardiol Rep       Date:  2000-02

2.  Images in cardiology: Thrombus after transcatheter closure of ASD with an Amplatzer septal occluder assessed by three dimensional echocardiographic reconstruction.

Authors:  P Acar; Y Aggoun; T Abdel-Massih
Journal:  Heart       Date:  2002-07       Impact factor: 5.994

3.  Transient ischemic attacks after long-term clamshell occluder implantation for closure of atrial septal defect.

Authors:  K C Prewitt; N S Gaither; A Farb; D C Wortham
Journal:  Am Heart J       Date:  1992-11       Impact factor: 4.749

4.  Healing response to the Clamshell device for closure of intracardiac defects in humans.

Authors:  J Kreutzer; C A Ryan; K Gauvreau; R Van Praagh; J M Anderson; K J Jenkins
Journal:  Catheter Cardiovasc Interv       Date:  2001-09       Impact factor: 2.692

5.  Transcatheter closure of secundum atrial septal defects using the new self-centering amplatzer septal occluder: initial human experience.

Authors:  J Masura; P Gavora; A Formanek; Z M Hijazi
Journal:  Cathet Cardiovasc Diagn       Date:  1997-12

6.  Evaluation of in vivo biocompatibility of different devices for interventional closure of the patent ductus arteriosus in an animal model.

Authors:  M Sigler; S Handt; M C Seghaye; G von Bernuth; R G Grabitz
Journal:  Heart       Date:  2000-05       Impact factor: 5.994

7.  Animal experimental implantation of an atrial septal defect occluder system.

Authors:  A Bloch Thomsen; M Schneider; U Baandrup; E V Stenbøg; J M Hasenkam; J P Bagger; G Hausdorf
Journal:  Heart       Date:  1998-12       Impact factor: 5.994

8.  Successful treatment of left atrial disk thrombus on an Amplatzer atrial septal defect occluder with abciximab and heparin.

Authors:  F E Willcoxson; J D R Thomson; J L Gibbs
Journal:  Heart       Date:  2004-05       Impact factor: 5.994

9.  Biological response to Bard Clamshell Septal Occluders in the canine heart.

Authors:  M A Kuhn; L A Latson; J P Cheatham; B McManus; J M Anderson; K L Kilzer; J Furst
Journal:  Circulation       Date:  1996-04-01       Impact factor: 29.690

10.  Evidence for circulating bone marrow-derived endothelial cells.

Authors:  Q Shi; S Rafii; M H Wu; E S Wijelath; C Yu; A Ishida; Y Fujita; S Kothari; R Mohle; L R Sauvage; M A Moore; R F Storb; W P Hammond
Journal:  Blood       Date:  1998-07-15       Impact factor: 22.113

View more
  18 in total

Review 1.  Atrial septum defect closure device in a beating heart, from the perspective of a researcher in artificial organs.

Authors:  Yasuko Tomizawa
Journal:  J Artif Organs       Date:  2012-06-23       Impact factor: 1.731

Review 2.  Stroke and peripheral embolism from an Amplatzer septal occluder 5 years after implantation.

Authors:  Claudia Stöllberger; Josef Finsterer; Elisabeth Krexner; Birke Schneider
Journal:  J Neurol       Date:  2008-06-13       Impact factor: 4.849

3.  Neointima-inducing inflow cannula with titanium mesh for left ventricular assist device.

Authors:  Yukiko Yamada; Tomohiro Nishinaka; Toshihide Mizuno; Yoshiyuki Taenaka; Eisuke Tatsumi; Kenji Yamazaki
Journal:  J Artif Organs       Date:  2011-07-07       Impact factor: 1.731

4.  Assessment of the healing process after percutaneous implantation of a cardiovascular device: a systematic review.

Authors:  Elodie Perdreau; Zakaria Jalal; Richard D Walton; Jérôme Naulin; Julie Magat; Bruno Quesson; Hubert Cochet; Olivier Bernus; Jean-Benoît Thambo
Journal:  Int J Cardiovasc Imaging       Date:  2019-11-19       Impact factor: 2.357

5.  Secondary residual shunt after atrial septal defect closure with an amplatzer occluder: surgical removal and evaluation of device biocompatibility after 7 years.

Authors:  Weihua Zhu; Henning Neubauer
Journal:  Pediatr Cardiol       Date:  2010-08-01       Impact factor: 1.655

6.  Bioabsorbable atrial septal occluder for percutaneous closure of atrial septal defect in children.

Authors:  Osman Baspinar; Mehmet Kervancioglu; Metin Kilinc; Ahmet Irdem
Journal:  Tex Heart Inst J       Date:  2012

Review 7.  Role of animal models for percutaneous atrial septal defect closure.

Authors:  Zakaria Jalal; Pierre-Emmanuel Seguela; Alban-Elouen Baruteau; David Benoist; Olivier Bernus; Olivier Villemain; Younes Boudjemline; Xavier Iriart; Jean-Benoit Thambo
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

8.  Intermediate and long-term followup of percutaneous device closure of fossa ovalis atrial septal defect by the Amplatzer septal occluder in a cohort of 529 patients.

Authors:  Munesh Tomar; Sanjay Khatri; Sitaraman Radhakrishnan; Savitri Shrivastava
Journal:  Ann Pediatr Cardiol       Date:  2011-01

9.  Fatal septicemia in a patient with cerebral lymphoma and an Amplatzer septal occluder: a case report.

Authors:  Claudia Stöllberger; Adam Bastovansky; Josef Finsterer
Journal:  J Med Case Rep       Date:  2011-11-24

10.  Transvenous closure of patent foramen ovale: preliminary results with a new self-expanding nitinol wire mesh in a Swine model.

Authors:  F Krizanic; M Sigler; H R Figulla
Journal:  Cardiol Res Pract       Date:  2009-09-09       Impact factor: 1.866

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.